Authors: Colombat, P Salles, G Brousse, N Eftekhari, P Soubeyran, P Delwail, V Deconinck, E Haioun, C Foussard, C Sebban, C Stamatoullas, A Milpied, N Boue, F Taillan, B Lederlin, P Najman, A Thieblemont, C Montestruc, F Mathieu-Boue, A Benzohra, A Solal-Celigny, P

Citation: P. Colombat et al., Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy forpatients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation, BLOOD, 97(1), 2001, pp. 101-106

Authors: Foran, JM Rohatiner, AZS Cunningham, D Popescu, RA Solal-Celigny, P Ghielmini, M Coiffier, B Johnson, PWM Gisselbrecht, C Reyes, F Radford, JA Bessell, EM Souleau, B Benzohra, A Lister, TA

Citation: Jm. Foran et al., European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma, J CL ONCOL, 18(2), 2000, pp. 317-324